Colossal Biosciences’ De-Extinction Science Could Also Advance Human Healthcare, CNBC Reports

At the CNBC AI Forum, CEO Ben Lamm said the work is opening new doors in genome engineering and developmental biology.

The science of de-extinction has implications for the environment, medicine and research on evolution, CNBC reported in October. Colossal Biosciences CEO and co-founder Ben Lamm told CNBC’s Julia Boorstin at the CNBC AI Forum in Dallas that the work is opening new doors in genome engineering and developmental biology. He said that could have implications for gene therapies, targeted delivery for humans and genetic diseases, as well as plastic in the oceans.

Lamm became interested in the field after a 2019 meeting with Harvard geneticist George Church, whose vision was to use CRISPR and other tools to bring back extinct species and apply some of those technologies to human healthcare. Colossal’s work includes the dodo, the Tasmanian tiger and the moa. Lamm said the real mission is to inspire the next generation about science, education and conservation while building a synthetic biology platform with many uses.

This story is based on original reporting by Colleen McKown for CNBC. Read the full feature on CNBC → https://www.cnbc.com/2026/10/10/de-extincting-dire-wolves-woolly-mammoths-help-humans.html